Unclassified GENotypes of Autoinflammatory Diseases and AA Amyloidosis

NCT ID: NCT06354322

Last Updated: 2025-09-02

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-02-26
• Study Completion Date: 2039-02-28

Brief Summary

Patients with autoinflammatory diseases (AID) have recurrent episodes of systemic inflammation accompanied by nonspecific elevation of blood inflammation markers typically absent between attacks. A complication of autoinflammatory diseases is AA amyloidosis, which can lead to renal failure and dialysis. Advances in genetic analysis have led to the identification of new autoinflammatory diseases and thus new pathophysiological pathways.

However, genetic analyses are sometimes confronted with results that are difficult to interpret. These are the Variants of Unknown Significance, for which genetic analysis alone does not allow to determine if the genetic mutation is responsible for the symptoms.

genetic analysis sometimes has limitations in the diagnosis of AID which can only be overcome by pathophysiological studies of the variants found.

Detailed Description

The study aim to explore variants of undetermined significance in major and minor patients with unclassified autoinflammatory disease or AA amyloidosis of undetermined etiology by studying their pathogenicity.

National multicenter research: internal medicine department of Tenon Hospital, pediatric department of Versailles Hospital and pediatric dermatology department of Necker Enfants Malades Hospital in Paris

Samples will be collected at the inclusion visit or at subsequent visits of the patient to the department during a blood draw performed as part of routine care by a registered nurse.

The total volume of the sample will be 24 mL per 6 month period maximum, and will not exceed In case of skin involvement of the auto-inflammatory disease, a skin biopsy may be performed as part of the patient's follow-up care.

Conditions

AA Amyloidosis; Autoinflammatory Disease

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

patients to be studied

No interventions assigned to this group

Control patients

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Patients over 18 years of age with the capacity to give express free and informed consent and;
• Minor patients under 18 years of age with both parents or legal guardians giving consent;
• Patients with unclassified IAD or AA amyloidosis of undetermined etiology;
• Patients followed in one of the study departments;
• Patients weighing more than 15 kg.

• Patients over 18 years of age with the capacity to give free and informed express consent;
• Patients with IAD classified with well-defined international criteria or ;
• Patients who have undergone cosmetic surgery or blood donors).

Exclusion Criteria

• Patients unable to give express free and informed consent;
• Subjects under guardianship, curatorship or safeguard of justice;
• Subjects who do not speak French;
• Subjects unable to answer questions or express themselves;
• Patients weighing less than 15 kg;
• Patients without social security coverage

• Minimum Eligible Age: 3 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Assistance Publique - Hôpitaux de Paris

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Service médecine interne-Hôpital Tenon

Paris, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Sophie GEORGIN-LAVIALLE, Professor

Role: CONTACT

sophie.georgin-lavialle@aphp.fr

00 33 1 56 01 72 04

Other Identifiers

APHP230630

Identifier Type: -

Identifier Source: org_study_id